Actualités sur Chemie

CROMA-PHARMA GmbH

Croma-Pharma announces enrollment of first patient in hyaluronic acid dermal filler clinical trial in China

Vienna (ots/PRNewswire) - Croma-Pharma® ('Croma') announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active ...

CROMA-PHARMA GmbH

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe

Vienna (ots/PRNewswire) - Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom ("UK"), and Ireland. Further markets including Brazil will follow by the end of 2023. The anaesthetic cream ...

Schweizerischer Nationalfonds / Fonds national suisse

The age of blood stains says more about the crime

Bern (ots) - The composition of blood stains changes over the course of weeks and months. Forensic medicine hopes to make use of this fact in future to convict suspects - or to prove their innocence. The blood-stained paper lay on the roof terrace for almost a year, protected from the rain but otherwise exposed to the elements. Fortunately it wasn't evidence of a violent crime; no, the drops of blood were part of a ...

Lysando AG

Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows

Hovione

Hovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery

Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that ...

Aurisco

Aurisco Expands Oligonucleotide Capacity and Launches New Website

SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...

Schweizerischer Nationalfonds / Fonds national suisse

If paradise were made of concrete

Aurisco

Aurisco Expands Oligonucleotide Capacity and Launches New Website

SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000TM solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...

Hovione

Hovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space

Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. The core feature of Ripple's Epidel® technology ...

Medison Pharma; Alnylam Pharmaceuticals

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

Zug, Switzerland (ots/PRNewswire) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their ...

Debiopharm International SA

Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions

Paris, France and Lausanne Switzerland (ots) - ● The round is co-led by M Ventures and Debiopharm Innovation Fund with Omnes Capital; all joining as new investors ● Series A will enable Iktos to expand its AI technology platform and launch Iktos Robotics; an AI-driven automated end-to-end drug discovery service ...

Hovione

Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise

Lisbon, Portugal (ots/PRNewswire) - Hovione, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall ...

Servier

Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients

Paris (ots/PRNewswire) - - Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe - The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies Servier, a global pharmaceutical company, today announced that the Committee for ...

VisIC Technologies

VisIC Technologies paves the way to high-power GaN traction inverters, successfully operating a BEV motor

Ness Ziona, Israel (ots/PRNewswire) - VisIC Technologies demonstrates an efficient Gallium Nitride based 3-phase traction inverter with an automotive-grade PMSM motor VisIC Technologies Ltd. successfully tested its 2.2mΩ 650V half-bridge power module, consisting of 4 parallel 8mΩ Power FET, in a 3-phase ...

Syqe Medical

Syqe Medical Announces Agreement with Israeli Ministry of Defence to Provide the SyqeAir Technology to Veterans

Tel Aviv, Israel (ots/PRNewswire) - Syqe Medical, the developer of innovative technologies in the world of medical devices, is pleased to announce the signing of an agreement with the Israeli Ministry of Defence to supply the SyqeAir Inhaler and Cartridges to all veterans prescribed medical cannabis by inhalation ...

Ionomr Innovations Inc.

Ionomr Innovations' Pemion® hydrocarbon-based proton exchange membrane and polymer exceed industry durability targets

Vancouver, Bc (ots/PRNewswire) - Pemion® affirms itself as a viable and advantageous option to conventional per-fluorinated materials Ionomr Innovations Inc.'s Pemion® has achieved performance and durability testing results that surpass internationally recognized standards from the US Department of Energy (US DOE) ...

ASK Chemicals Group

ASK Chemicals refinances senior credit facilities

Hilden, Germany (ots/PRNewswire) - The new financing provides for a €225 million senior secured term loan alongside a €40 million multi-currency senior revolving credit facility. ASK Chemicals, a leading global supplier of high-performance industrial resins and materials, today announced that it has signed definitive agreements to refinance the company's existing senior secured credit facilities; consisting of a ...

Hovione

Hovione and GEA announce a strategic collaboration to advance Continuous Tableting

Lisbon, Portugal (ots/PRNewswire) - Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s development and manufacturing experience and both parties commit to partner to accelerate ...

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule

Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...

Tikun Olam Cannbit

Cannbit-Tikun Olam begins cannabis extracts export from Israel to Europe at the largest commercial quantity to date

Tel Aviv, Israel (ots/PRNewswire) - Cannbit-Tikun Olam Israel(TASE:TKUN), Israel's medical cannabis pioneer, today announced that the first commercial shipment of medical cannabis extracts produced by the company was making its way to Germany. It marks the largest volume of cannabis extracts exported from Israel to ...

Acousia Therapeutics GmbH

Hearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...

Saudi Aramco

Aramco affiliate S-OIL to build one of the world's largest petrochemical crackers in South Korea

Dhahran, Saudi Arabia (ots/PRNewswire) - - Biggest ever Aramco investment in South Korea contributes to a stable supply of feedstock - First commercial deployment of Aramco's TC2C™ thermal crude to chemicals technology developed in collaboration with Lummus Technology - S-OIL's chemical yield based on volume ...

Hallura Ltd.

"Click Chemistry" Concept Inspires BiOLinkMatrix by HALLURA™: the Next Generation of HA Dermal Fillers

Yokneam, Israel (ots/PRNewswire) - Harnessing the 2022 Nobel Prize Awarded Click Chemistry Concept, Hallura's Products Revolutionize the Way Hyaluronic Acid is Crosslinked in Dermal Fillers Hallura Ltd., an Israeli aesthetic medical company, announced today that its proprietary technology named the BiOLinkMatrix ...

TES Pharma

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

Perugia, Italy (ots/PRNewswire) - INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and ...